论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liang C, Li W, Ge H, Zhang KT, Li GM, Wu J
Received 15 September 2017
Accepted for publication 13 March 2018
Published 27 April 2018 Volume 2018:11 Pages 2387—2397
DOI https://doi.org/10.2147/OTT.S151751
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Background and aim: Beclin1 has been reported as a vital marker for a number of malignant
tumors. However, the role of Beclin1 in hepatocellular carcinoma (HCC) remains
inconclusive. Thus, we conducted a meta-analysis to assess the correlation
between Beclin1 and its clinicopathological and prognostic values in HCC.
Methods: PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI, and
Chinese WanFang databases were searched for published articles on Beclin1
expression in hepatocellular tissues. Standard-compliant articles were screened
using the Newcastle–Ottawa Scale for strict quality control of the literature.
The correlation of Beclin1 expression with the clinicopathological features and
survival outcomes was analyzed. Pooled odds ratios and hazard ratios with 95%
confidence intervals were calculated using STATA14.2.
Results: Eleven articles with 1,279 patients were included in this
meta-analysis. Positive Beclin1 expression was found to be correlated with
alpha fetoprotein, liver cirrhosis, and vascular invasion, but not with gender,
age, HBsAg, size of tumor, number of tumors, differentiation, and TNM stage.
Positive Beclin1 expression was also associated with favorable 5-year overall
survival and disease-free survival rates.
Conclusion: Our meta-analysis indicated that positive Beclin1 expression was
negatively related to alpha fetoprotein, liver cirrhosis, and vascular invasion
in HCC. Beclin1 could be used as a prognostic biomarker for HCC.
Keywords: Beclin1, hepatocellular carcinoma, prognosis, meta-analysis